SCHEMBL4350834

SCHEMBL4350834

Cc1ccc(S(=O)(=O)n2ccc3nc(CNC(=O)C45CCC(N(C(=O)O)C(C)(C)C)(CC4)CC5)cnc32)cc1

nearest known ligand 0.34

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.34
SLC1A3 P43003 1/20 0.32
SLC1A2 P43004 1/20 0.32
SLC1A1 P43005 1/20 0.32
RAB9A P51151 2/20 0.32
PTPN11 Q06124 1/20 0.32
POLB P06746 1/20 0.31
TRPA1 O75762 1/20 0.30
OPRM1 P35372 1/20 0.30
VEGFA P15692 1/20 0.30
EGLN1 Q9GZT9 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4347399 0.85 L3MBTL1 (0.37) L3MBTL1SLC1A3SLC1A2SLC1A1RAB9A
SCHEMBL4351093 0.82 NAMPT (0.36) L3MBTL1SLC1A3SLC1A2SLC1A1POLB
SCHEMBL4350836 0.82 L3MBTL1 (0.36) L3MBTL1PTPN11VEGFAEGLN1
SCHEMBL2318672 0.80 L3MBTL1 (0.46) L3MBTL1SLC1A3SLC1A2SLC1A1RAB9A
SCHEMBL2359779 0.78 L3MBTL1 (0.45) L3MBTL1SLC1A3SLC1A2SLC1A1RAB9A
SCHEMBL1933424 0.77 L3MBTL1 (0.43) L3MBTL1SLC1A3SLC1A2SLC1A1PTPN11
SCHEMBL12389611 0.76 CA12 (0.42) L3MBTL1POLB
SCHEMBL18855846 0.73 L3MBTL1 (0.49) L3MBTL1POLB
SCHEMBL1536085 0.73 HPGD (0.47) POLB
SCHEMBL20684438 0.72 L3MBTL1 (0.48) L3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180291029-A1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC. (US) 2018-10-11 US disclosed
US-20160326181-A1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC. (US) 2016-11-10 US disclosed
EP-3031324-A2 TRICYCLIC KINASE INHIBITORS AbbVie Inc. (US) 2016-06-15 EP disclosed
US-9365579-B2 Tricyclic compounds ABBVIE INC. (US) 2016-06-14 US disclosed
EP-2299821-B1 TRICYCLIC COMPOUNDS ABBVIE INC (US) 2015-11-04 EP disclosed
US-20150210708-A1 NOVEL TRICYCLIC COMPOUNDS ABBVIE INC. (US) 2015-07-30 US disclosed
US-8962629-B2 Tricyclic compounds ABBVIE INC. (US) 2015-02-24 US disclosed
US-20090312338-A1 Novel Tricyclic Compounds ABBOTT LABORATORIES (US) 2009-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180291029-A1 NOVEL TRICYCLIC COMPOUNDS CYP11B2, CYP11B1, ABCB1 L3MBTL1 4170/4885SLC1A3 2710/4885SLC1A2 2351/4885
US-20090312338-A1 Novel Tricyclic Compounds CYP11B2, CYP11B1, ABCB1 L3MBTL1 4170/4885SLC1A3 2710/4885SLC1A2 2351/4885
US-20160326181-A1 NOVEL TRICYCLIC COMPOUNDS CYP11B2, CYP11B1, ABCB1 L3MBTL1 4170/4885SLC1A3 2710/4885SLC1A2 2351/4885
US-20150210708-A1 NOVEL TRICYCLIC COMPOUNDS CYP11B2, CYP11B1, ABCB1 L3MBTL1 4170/4885SLC1A3 2710/4885SLC1A2 2351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.